betaxolol has been researched along with Lung Neoplasms in 2 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 8.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 7.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 4.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 3.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yen, CF | 2 |
| Hsu, CK | 1 |
| Yang, HS | 1 |
| Lee, CN | 1 |
| Chi, CC | 1 |
| Chung, WH | 2 |
| Wang, CL | 2 |
| Pang, JS | 1 |
| Wang, CW | 1 |
| Ko, YS | 2 |
| Lu, CW | 2 |
| Wang, TY | 1 |
| Chen, KH | 1 |
| Wu, CE | 1 |
| Hsu, PC | 1 |
| Fang, YF | 1 |
| Li, SH | 1 |
| Ko, HW | 1 |
| Tseng, LC | 1 |
| Shih, FY | 1 |
| Lin, YJ | 1 |
| Chen, MJ | 1 |
| Chen, CB | 1 |
| Su Pang, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitor-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study[NCT05165082] | 8 participants (Actual) | Interventional | 2021-12-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for betaxolol and Lung Neoplasms
| Article | Year |
|---|---|
Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Topics: Administration, Topical; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Ant | 2020 |
Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.
Topics: Antineoplastic Agents; Betaxolol; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studi | 2021 |